Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913539 | 0.82 | MRGPRX4 (0.32) | CYP1A2POLBMRGPRX4MAPKAPK2 | |
| SCHEMBL7573577 | 0.81 | ADORA3 (0.42) | KDM4ELMNATSHRMRGPRX4 | |
| SCHEMBL20198550 | 0.74 | MRGPRX4 (0.32) | MRGPRX4 | |
| SCHEMBL1760358 | 0.74 | HCAR2 (0.41) | CYP1A2POLBSMN1; SMN2KDM4ELMNA | |
| SCHEMBL15272578 | 0.74 | MRGPRX4 (0.38) | SMN1; SMN2MRGPRX4 | |
| SCHEMBL24993307 | 0.74 | P2RX7 (0.42) | CYP1A2KDM4ECYP3A4MRGPRX4 | |
| SCHEMBL15006457 | 0.74 | BAZ2B (0.47) | BAZ2B | |
| SCHEMBL830961 | 0.73 | NOS3 (0.36) | — | |
| SCHEMBL14872363 | 0.70 | MRGPRX4 (0.57) | MRGPRX4 | |
| SCHEMBL13765790 | 0.69 | BAZ2B (0.42) | BAZ2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | NAT1, AADAC, ACACA | BAZ2B 2278/4885CYP1A2 32/4885POLB 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.